Regular Article

blood

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

Human CD62L^dim neutrophils identified as a separate subset by proteome profiling and in vivo pulse-chase labeling

Tamar Tak,[1] Patrick Wijten,[2] Marjolein Heeres,[1] Peter Pickkers,[3] Arjen Scholten,[2] Albert J. R. Heck,[2] Nienke Vrisekoop,[1] Luke P. Leenen,[4] José A. M. Borghans,[5] Kiki Tesselaar,[5] and Leo Koenderman[1]

[1]Department of Respiratory Medicine and Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands; [2]Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands; [3]Intensive Care Department, Radboud University Medical Centre, Nijmegen, The Netherlands; and [4]Department of Trauma Surgery and [5]Department of Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands

---

Key Points

- CD62L^dim neutrophils seen in acute inflammation are of an age similar to that of segmented neutrophils; banded neutrophils are immature cells.

- CD62L^dim neutrophils cluster separately from banded and normal segmented neutrophils based on proteome profiling.

During acute inflammation, 3 neutrophil subsets are found in the blood: neutrophils with a conventional segmented nucleus, neutrophils with a banded nucleus, and T-cell–suppressing CD62L^dim neutrophils with a high number of nuclear lobes. In this study, we compared the in vivo kinetics and proteomes of banded, mature, and hypersegmented neutrophils to determine whether these cell types represent truly different neutrophil subsets or reflect changes induced by lipopolysaccharide (LPS) activation. Using in vivo pulse-chase labeling of neutrophil DNA with 6,6-^{2}H$_2$-glucose, we found that ^{2}H-labeled banded neutrophils appeared much earlier in blood than labeled CD62L^dim and segmented neutrophils, which shared similar label kinetics. Comparison of the proteomes by cluster analysis revealed that CD62L^dim neutrophils were clearly separate from conventional segmented neutrophils despite having similar kinetics in peripheral blood. Interestingly, the conventional segmented cells were more related at a proteome level to banded cells despite a 2-day difference in maturation time. The differences between CD62L^dim and mature neutrophils are unlikely to have been a direct result of LPS-induced activation, because of the extremely low transcriptional capacity of CD62L^dim neutrophils and the fact that neutrophils do not directly respond to the low dose of LPS used in the study (2 ng/kg body weight). Therefore, we propose CD62L^dim neutrophils are a truly separate neutrophil subset that is recruited to the bloodstream in response to acute inflammation. This trial was registered at www.clinicaltrials.gov as #NCT01766414. (*Blood*. 2017;129(26):3476-3485)

Introduction

Neutrophils engage in the resolution of infection by phagocytosing and killing pathogens. Decreased functionality of neutrophils can lead to infectious complications and even sepsis.[1] Conversely, hyperactivation can lead to severe proinflammatory conditions such as acute respiratory distress syndrome. Neutrophils are involved in the balance of hyper- and hypoactivation of the immune system by releasing proinflammatory and toxic mediators[2,3] and by suppressing excessive immune responses.[4]

Acute inflammation induces recruitment of neutrophil phenotypes into the peripheral blood that are not present in either circulation or the marginated pool during homeostasis.[5] Several studies have identified such inflammatory phenotypes focusing on different characteristics, such as differential expression of 3-fucosyl-N-acetyl-lactosamine (CD15) and Fc-γ receptor-III (CD16),[6] interleukin-4Rα (CD124) expression,[7] low buoyant density,[8] arginase expression,[9] or immunomodulatory functionality.[10] On the basis of the differential expression of CD16 and L-selectin (CD62L),[11] we have identified at least 3 different subsets of inflammatory neutrophils: (1) neutrophils with a

segmented nuclear morphology resembling prototypically mature blood neutrophils characterized by CD16^bright/CD62L^bright expression (segmented), (2) CD16^dim/CD62L^bright cells with a banded nuclear morphology (banded), and (3) CD16^bright/CD62L^dim cells with on average a larger number of nuclear lobes (although not as high as in foliate deficiency–induced hypersegmentation) that are capable of suppressing T-cell proliferation (CD62L^dim).[11]

The 3 neutrophil subsets have been observed in a range of acute inflammatory diseases, including sepsis,[11] severe trauma,[11] burns, and cancer.[12] Because of their opposing pro- and anti-inflammatory functions, manipulation of neutrophil subset release and development might allow for steering the acute immune response. This can be achieved, for example, by activating CD62L^dim neutrophils during hyperinflammatory conditions or by inhibiting CD62L^dim neutrophils to counteract the compensatory anti-inflammatory response syndrome in severely ill patients.[13] Very little is known about the origins of these subsets, however. It is commonly thought that the increase in nuclear segmentation is associated with increasing cellular age,[4,14] because

---

banded neutrophils have been shown to be younger cells in patients with cancer,[15,16] and CD62L[dim] neutrophils have been shown to be aged cells in mice.[17] In humans, however, hypersegmented neutrophils that are observed in pernicious anemia are thought to directly mature from banded cells into hypersegmented cells.[18] In addition, in vivo ^{3}H-thymidine labeling in a patient with pernicious anemia showed that labeled hypersegmented neutrophils started to appear in circulation at the same time as normal neutrophils, although the peak in labeling of the hypersegmented neutrophils was observed 1 day later. Taken together, the conflicting data on CD62L[dim] neutrophils in mice and hypersegmented neutrophils in patients with pernicious anemia illustrate that it remains an open question whether the CD62L[dim] neutrophil subset observed in acute inflammation represents aged cells.

All 3 subsets are detected in the bone marrow during homeostasis,[19,20] but little is known regarding the presence of these cells outside the bone marrow or their relative numbers at the different tissue sites. The human endotoxemia model is a valuable model to study acute systemic inflammation[21] and induces changes in blood immune cells reminiscent of those found in septic[22,23] or severely injured patients.[24] These conditions induce the recruitment of banded and CD62L[dim] neutrophils into the blood. Transcriptome analyses of neutrophil subsets in the human endotoxemia model[25,26] revealed large differences between banded and CD62L[dim] neutrophils, but these studies did not relate these differences to the segmented neutrophil subset. Moreover, characterization of neutrophil subsets by transcriptome analysis is hampered by the fact that these cells have a low transcriptional capacity,[27] and many changes in protein expression levels may not be reflected by changes in messenger RNA (mRNA) expression. For example, most granule proteins are produced and stored during maturation in the bone marrow[3,28] and can be lost by degranulation. These changes will be missed by mRNA analysis.

Our study was designed to gain more insight into the properties and origins of the 3 neutrophil subsets found in acute inflammation. In vivo pulse-chase deuterium [2]H-labeling was performed to determine the maturation times of the different subsets observed during acute inflammation. In addition, we performed high-end proteomic analysis on purified blood neutrophil subsets to assess differences among the 3 subsets.

Materials and methods

Participants

Samples were obtained from 20 healthy male volunteers who participated in a human endotoxemia trial (registered at www.clinicaltrials.gov as #NCT01766414), in which 10 volunteers were treated with C1-esterase inhibitor and 10 were treated with a placebo. The study was approved by the ethics review board of the Radboud University Medical Centre and conducted in compliance with the Declaration of Helsinki (adapted by World Medical Association General Assembly, Fortaleza, Brazil, 2013), International Conference on Harmonisation Good Clinical Practice guidelines, and the rulings of the Dutch Medical Research Involving Human Subjects Act. Written informed consent was obtained from all study participants. Participants were screened and found healthy based on physical examination, electrocardiography, and hematological laboratory values. All volunteers were negative for HIV and hepatitis B antibodies in serum. Participants with febrile illness <2 weeks before LPS injection were excluded, as were those taking prescription drugs. Participants were asked to refrain from caffeine and alcohol use in the 24 hours before LPS challenge and to refrain from food intake 12 hours before LPS challenge.

In vivo ^{2}H labeling

The relative age of neutrophil subsets was determined using in vivo ^{2}H labeling, as described previously.[29,30] In short, all 20 volunteers were asked to drink 12 doses every 30 minutes of 6.67 g of metabolic-grade 6,6-[2]H$_2$-glucose (total, 80 g; Cambridge Isotope Laboratories, Tewksbury, MA) at 3 to 11 days before LPS administration (as described in the following paragraph). The 6,6-[2]H$_2$-glucose label is metabolized and incorporated into the DNA of all dividing cells via the de novo nucleotide synthesis pathway.[17,18] During the labeling procedure, blood was collected by finger prick to determine the availability of label in plasma, as described previously.[30]

Experimental endotoxemia model

LPS challenge was performed according to a strict protocol, as described previously.[31] In short, after admission to the research medium care unit of the Radboud Medical Centre, heart rate and blood pressure were monitored starting at t = −1 hour until discharge at t = 8 hours. A cannula was placed in an antecubital vein to permit infusion of hydration fluid (1.5 L; 2.5% glucose, 0.45% saline) from t = −1 hour until t = 0 hours. Then a single dose of 2 ng per kilogram of bodyweight LPS (US Standard Reference Endotoxin *Escherichia coli* O:113, obtained from the Pharmaceutical Development Section of the National Institutes of Health, Bethesda, MD) was injected (t = 0 hours). LPS injection was followed by continuous infusion of hydration fluid (2.5% glucose, 0.45% saline; 150 ml/h) from t = 0 to t = 8 hours. The course of LPS-induced symptoms (headache, shivering, nausea, vomiting, muscle pain, and back pain) was scored every 30 minutes on a 6-point Likert scale (0 = no symptoms; 5 = very severe symptoms; vomiting = 3 points), adding up to a maximum of 28 points.[32] White blood cell counts were analyzed on a routine hematocytometer at t = 0, 1, 2, 6, and 8 hours.

Neutrophil isolation

Leukocytes were isolated from blood anticoagulated with sodium heparin 5 minutes before injection of LPS and at 1, 3, 6, and 8 hours after LPS injection. After erythrocyte lysis in ice-cold isotonic erythrocyte lysis buffer (150 mM NH$_4$Cl, 10 mM KHCO$_3$, and 0.1 mM NA$_2$EDTA), leukocyte preparations were stained with antibodies in phosphate-buffered saline supplemented with 0.32% trisodium citrate and 10% human pasteurized plasma solution (Sanquin, Amsterdam, The Netherlands): CD14-ECD (clone RMO52; Beckman Coulter, Pasadena, CA) and CD62L-PE (clone SK11) and CD16-Alexa647 (clone 3G8; both from BD Biosciences, San Jose, CA). Neutrophil subsets were sorted using an AriaIII fluorescence-activated cell sorter (FACS; BD Biosciences). Neutrophils were identified based on a forward scatter/side scatter granulocyte gate; doublet exclusion was based on side scatter height/width and CD14[−] expression. Subsequently, neutrophil subsets were sorted as CD16[dim]/CD62L[bright] (banded), CD16[bright]/CD62L[bright] (segmented), and CD16[bright]/CD62L[dim] (CD62L[dim]; supplemental Figure 1, available on the *Blood* Web site). Sorted populations were reanalyzed and typically >99% pure.

Neutrophil nuclear morphology

Neutrophil nuclear morphology was determined by manual counting of May-Grünwald-Giemsa–stained cytospins by an experienced technician in a blinded manner. The microscope used was a Leica DMRXE microscope equipped with a 100× oil immersion objective (Leica Microsystems, Wetzlar, Germany). A strict definition was used to identify a separation between lobes in such a way that these were only scored when the connection between lobes was <33% of the width of the adjacent lobes.

Determination of ^{2}H enrichment

DNA was isolated from sorted cell populations using a NucleoSpin blood kit (Macherey-Nagel, Düren, Germany) and hydrolyzed and derivatized to pentafluoro triacetate, as described in detail previously.[30] Relative quantities of unlabeled and [2]H-labeled adenosine–derived pentafluoro triacetate were determined with an Agilent 7980A/5975C GC-MS in negative chemical ionization mode scanning for m/z 435 (M+0, unlabeled) and m/z 437 (M+2, labeled). Resulting enrichments were corrected for natural background

Figure 1. Kinetics of white blood cells and neutrophil subsets after LPS injection. (A) Neutrophil counts were decreased 1 hour after LPS injection (t = 0), followed by increased counts. (B) Counts of other leukocytes were also decreased at t = 1 hour, but most had recovered by t = 6 or 8 hours. (C) Different neutrophil subsets were identified (t = 3 hours) based on CD16 and CD62L expression. (D) The appearance of the banded and CD62L^{dim} subsets was followed over time. (E) After sorting, microscopic analysis of the different subsets isolated at t = 3 hours post–LPS challenge revealed an increasing nuclear lobularity from banded to segmented to CD62L^{dim} neutrophils. Symbols and bars represent mean ± 95% CI (n = 20) (A,B,D) or medians ± interquartile range (n = 7-8) (E). $*P < .05$, $**P < .01$, $***P < .001$, and $****P < .0001$ compared with t = 0 hours, as determined by repeated-measures 1-way analysis of variance with Dunnett's or Holm-Sidak correction for multiplicity where applicable.

enrichment and availability of 6,6-^{2}H$_2$-glucose in plasma, as described previously.[30]

Protein identification and quantification

A detailed description of the proteomic approach and western blot analyses of several candidate proteins can be found in supplemental Methods and in supplemental Figure 2. In short, 3×10^6 cells of the different neutrophil subsets were isolated from blood derived from 3 volunteers in the placebo group 3 hours after LPS infusion, because at this time point, the largest number of cells from the different subsets were present. Cells of each subset were digested with trypsin, labeled with a different label for each subset, and pooled in a 1:1:1 ratio for each individual participant. This approach allows for internally controlled quantification of the mass spectrometry data.

Samples were fractionated using strong cation exchange chromatography. Fractions were analyzed using an LTQ-Orbitrap liquid chromatography–tandem mass spectrometry (LC-MS/MS).[33] Peptides were identified by searching the resulting peak lists against the Uniprot database (*Homo sapiens*), with exclusion of common contaminants. Because glucose is not used for amino acid production and glycosylated peptides were not measured, in vivo ^{2}H labeling should not have affected protein quantifications. All results have been deposited in the ProteomeXchange Consortium via the PRIDE partner repository (data set identifier PXD001674; DOI: 10.6019/PXD001674).[34]

Hierarchical clustering

Hierarchical clustering was employed to quantify the dissimilarities between the neutrophil subsets and the individual samples. Proteins detected or reliably quantified in only 1 of 3 individuals in any of the subsets were excluded from analysis. Remaining missing values were mean imputed. Using the pvclust

plugin (version 1.3-0) for R (version 3.1.1), a Euclidean dissimilarity matrix was calculated from protein abundances and clustered hierarchically using the averages method. Significance of the resulting clusters was tested with multiscale bootstrapping (10 000 repeats) and reported as approximate unbiased P values ± 95% CIs of the P values.[35]

Clustering of protein expression data

Sums of protein quantifications from 3 individual samples were standardized to an average expression of 0, with a standard deviation of 1. Proteins with missing values for ≥2 individuals in any of the 3 subsets were excluded from analysis. Standardized expression profiles were subjected to Fuzzy C-means clustering using R with the Mfuzz plugin (version 2.3.1).[36] In addition to assigning each protein to a cluster, fuzzy clustering indicates how well each protein fits in each cluster. By choosing a minimal required membership value, outliers are excluded from analysis, making fuzzy clustering preferable over hard clustering methods such as the k-means method.

The required number of clusters was determined by calculating the average centroid distance for clustering runs with 2 up to 40 clusters.[37] After 7 clusters, addition of extra clusters hardly improved the clustering results. Thus, the number of clusters was set to 7. To prevent clustering of random data while keeping the false-negative rate as low as possible, the optimal value for fuzzifier parameter m was calculated as described previously,[37] resulting in a value of 3.69.

GO enrichment analysis

Proteins with cluster membership values of at least 0.33 were analyzed by gene ontology (GO) enrichment analysis. Gene names of identified proteins were obtained from the Uniprot database. Subsequently, GO terms of biological

Figure 2. Label kinetics in plasma and in DNA of neutrophil subsets. Healthy volunteers were labeled with 6,6^{2}H$_2$-glucose over the course of 6 hours. (A) During this period, the availability of label was monitored by measuring the fraction of 6,6-^{2}H$_2$-glucose in the total blood glucose pool in blood samples obtained by skin pricks. (B) DNA ^{2}H enrichment of the different inflammatory neutrophil subsets 3 hours after LPS injection or total neutrophils isolated 5 minutes pre-LPS injection at 3 to 11 days after 6,6-^{2}H$_2$-glucose. Results suggest that banded neutrophils are less mature than the 2 other subsets. (A) Fraction enrichment was corrected for availability of label for each individual. Symbols indicate mean ± standard deviation, with (A) n = 20 and (B) n = 4 volunteers at each time point, with a total of 20 volunteers. *P < .05 for banded compared with segmented neutrophils, #P < .05 for banded neutrophils compared with neutrophils isolated before LPS injection, and ***P < .001 for banded neutrophils compared with all 3 other subsets as determined by a repeated-measures 2-way analysis of variance with Tukey's correction for multiplicity.

processes, molecular functions, and cellular components were obtained for each protein and analyzed using the GO enrichment analysis and visualization tool (GOrilla; accessed 20 January 2015).[38,39] Enrichment was determined for proteins in each cluster compared with the background set of all identified proteins using an exact mHG P value computation, corrected for multiplicity using the Benjamini and Hochberg[40] false-discovery rate correction.[38] Because this resulted in a list of up to 120 significantly enriched GO terms in a cluster, results were summarized by removing highly similar GO terms with REViGO and visualized in R using the ggplot2 plugin (version 0.9.3.1).[41]

Statistics on clinical data

Clinical data were tested for significant deviation from t = 0 using 1-way repeated-measures analysis of variance, with P values corrected for multiplicity using Dunnett's correction.

Results

Kinetics of clinical and inflammatory parameters after endotoxin challenge

As shown previously,[42] infusion of LPS (2 ng/kg) in healthy volunteers induced clinical symptoms reminiscent of systemic inflammatory response syndrome. Disease scores were increased 1.5 hours after LPS injection, followed by an increase in heart rate and body temperature at 2 to 5.5 hours post-LPS (supplemental Figure 3). The mean arterial pressure decreased from 2 hours after LPS injection until the end of the experiment.

Blood counts of all leukocytes were decreased 1 hour after LPS injection (Figure 1A-B). Circulating monocyte numbers had normalized after 6 hours, whereas lymphocyte, eosinophil, and basophil numbers remained low until 8 hours after LPS injection. After an initial decrease in neutrophil numbers at 1 hour after LPS, numbers increased to levels 2.5-fold higher than the pre-LPS count. FACS analysis revealed 3 neutrophil subsets based on CD16/CD62L expression (Figure 1C), which were present at 3 and 6 hours post-LPS challenge (Figure 1D). Microscopic examination of sorted subsets showed an increased average number of nuclear lobes in the CD16^{bright}/CD62L^{dim}

population and a banded nuclear phenotype for the CD16^{dim}/CD62L^{bright} population (Figure 1E).[11]

In vivo ^{2}H labeling

Because neutrophil progenitors do not proliferate after the myelocyte stage, in vivo 6,6-^{2}H$_2$-glucose labeling can be used to determine the time required for the different subsets to mature and be released into the bloodstream. In contrast to deuterium labels such as ^{2}H$_2$O, 6,6-^{2}H$_2$-glucose has a rapid turnover in the circulation (Figure 2A) and is rapidly metabolized. This allows the application of a short labeling pulse followed by a chase experiment. To correct for differences in label uptake between volunteers, the availability of label was determined in the plasma of each volunteer (Figure 2A). Corrected DNA ^{2}H kinetics under homeostatic conditions were determined on neutrophils isolated before injection of LPS. In these cells, the first ^{2}H was detected in peripheral blood neutrophil DNA at day 7 after intake of label (Figure 2B). This is in line with the notion that conventional neutrophils mature approximately 6 days in the bone marrow after the last division of their progenitors (myelocytes).[29] Segmented neutrophils isolated at 3 hours post-LPS injection showed ^{2}H-enrichment curves similar to neutrophils isolated under homeostatic conditions, suggesting that the maturation kinetics of segmented neutrophils were not affected by LPS. CD62L^{dim} neutrophils also showed similar ^{2}H-enrichment kinetics to homeostatic neutrophils, with the highest enrichment at 7 days after intake of label. In contrast, the banded neutrophil subset showed a different DNA ^{2}H enrichment, with highest enrichment measured as early as 5 days postlabel intake, suggesting that maturation into a banded cell takes approximately 2 days less than maturation into the 2 other phenotypes. No significant differences in labeling kinetics were observed between placebo- and C1 inhibitor–treated groups (supplemental Figure 4). Thus, labeling could be combined from both treatment groups, providing additional statistical power.

Hierarchical clustering of neutrophil subsets based on protein expression data

Proteome analysis by LC-MS/MS identified and quantified 2161 unique proteins in the 3 neutrophil subsets obtained from 3 individuals 3 hours after LPS injection (supplemental Table 2). LC-MS/MS protein

Figure 3. Hierarchical clustering of protein expression data. (A) Heatmap of normalized protein expression profiles. (B) Hierarchical clustering of non-normalized protein expression using averages clustering on a Euclidean distance matrix. Clusters were tested for statistical significance using multiscale bootstrapping, which revealed 4 statistically significant clusters (indicated by red boxes): 1 for each neutrophil subset and 1 for the banded and segmented neutrophils together. *P* values are approximately unbiased (AU; ie, an AU *P* value of .95 indicates that the existence of 2 clusters is supported by the data with 95% confidence). Numbers between brackets indicate the standard error of the AU *P* value estimation.

quantification was validated for several proteins with different expression patterns across the 3 subsets (supplemental Figure 2) by western blotting or by comparison with previously published FACS data.[11] All tested proteins showed highly similar expression patterns with the different techniques, even though results obtained by western blotting showed a larger variability than those obtained by LC-MS/MS.

The relations between the 3 neutrophil subsets and each replicate were assessed using hierarchical clustering on proteins with no more than 1 missing value in each of the subsets (Figure 3; 1755 of 2161 proteins). For hierarchical clustering, a Euclidean dissimilarity matrix was created to determine the correlation between all samples. Subsequently, a dendrogram was created to visualize the relations between samples (Figure 3B). Replicates of each subset clustered tightly together in this dendrogram. Using multiscale bootstrapping, we determined that the existence of these clusters was supported by our data with a probability of >99.9%.[35] At the proteome level, banded and segmented neutrophils correlated better and were distinctly separated from the CD62L[dim] neutrophils. Use of normalized protein expressions or different distance matrix calculations did not result in formation of different clusters (data not shown).

### Characterization of neutrophil subsets by proteome analysis

To further examine the relation between the 3 neutrophil subsets, protein expression profiles were examined using functional enrichment

analysis. To this end, proteins were first clustered based on their relative expression between the 3 subsets. Before clustering, the optimal number of protein clusters was determined to be 7, because addition of extra clusters did not lead to better results. The resulting protein clusters were clearly different in their relative expression between the 3 neutrophil subsets (Figure 4). A total of 618 proteins had an expression pattern that differed too much from the 7 clusters to be assigned to any of the clusters and were treated as a separate cluster.

Subsequently, GO enrichment analysis was performed on the 7 clusters of proteins and the cluster of nonclassified proteins. GO terms describe biological processes, molecular functions, or cellular components and are annotated to genes/proteins based on evidence from literature. GO enrichment analysis revealed significant GO-term enrichments in clusters 1, 2, 4, and 6. (Table 1 lists the 10 most significantly enriched GO terms in each cluster, and supplemental Table 3 provides the complete list of enrichments).

Using ReViGO, highly similar GO terms were removed from clusters with significant enrichments, and remaining GO terms for biological processes were clustered based on semantic similarity (Figure 5). Thereby, enrichments of protein functions could clearly be recognized. Cluster 1, which consisted of 336 proteins upregulated in CD62L[dim] neutrophils, contained genes involved in adhesion and activation, response to stimuli, regulation of these responses, and regulation of the immune system in general. Cluster 2, consisting of 238 proteins with a lower expression in CD62L[dim] neutrophils,

Figure 4. Clustering of protein expression profiles. Clustering analysis divides normalized protein expression patterns into 7 distinct clusters. Three clusters have high expression in 1 subset compared with the others (clusters 1, 3, and 5 for CD62L^{dim}, banded, and segmented neutrophils, respectively), 2 clusters have decreased expression in 1 subset (clusters 2 and 7 for CD62L^{dim} and banded neutrophils, respectively), and 2 clusters have gradually increasing (cluster 6) or decreasing (cluster 4) protein expression levels from banded to segmented and CD62L$_{dim}$. Each line represents the expression pattern of 1 protein. Line colors indicate the cluster membership value (ie, the higher the membership value, the more similar to the cluster average). A minimum cluster membership value of 0.33 was used for further analysis. Numbers between brackets indicate the number of proteins in each cluster with cluster membership values above 0.33.

showed enrichment of proteins involved in protein shuttling, ribosomal proteins, and proteins involved in RNA metabolism, splicing, and translation. Similarly, cluster 4, which contained 337 proteins gradually reduced from banded via segmented to CD62L^{dim} neutrophils, consisted mostly of proteins involved in mRNA processing and biosynthesis. Lastly, cluster 6 contained 358 proteins with a lower expression in banded neutrophils, compared with segmented and CD62L^{dim} neutrophils. This cluster showed enrichment in proteins involved in nucleotide metabolism, major histocompatibility complex class I antigen presentation, protein degradation, and suppression of the Wnt signaling pathway. Taken together, these data implicate differential functionalities for the different neutrophil subsets.

Discussion

Our data challenge the hypothesis that the different neutrophil subsets (banded, segmented, and CD62L^{dim} cells) follow a linear differentiation from banded (immature) to segmented (mature) to CD62L^{dim} (aged), as is the consensus in the field.[4,11,12] After pulse-chase labeling with 6,6-^{2}H$_2$-glucose, labeled banded neutrophils were observed several days earlier in the blood than labeled segmented and CD62L^{dim} neutrophils. Because ^{2}H labeling of DNA only takes place during the S phase of the cell cycle, these data demonstrate that banded neutrophils observed in acute inflammation take less time to mature from myelocytes than the other 2 subsets and are therefore likely to be cells prematurely mobilized from the bone marrow.[43,44] These data are in agreement with those of previous studies in patients with cancer.[15,16] This mobilization is generally thought to be a compensation of the bone marrow to release as many neutrophils as possible, even if some of those are not yet fully mature and might have a low capacity for clearing pathogens.[45] Functional enrichment analysis supported the hypothesis

that banded neutrophils are immature cells still in the process of producing large amounts of proteins, because these cells showed the highest expression of proteins involved in de novo protein synthesis (Figure 5; supplemental Figure 5). CD62L^{dim} neutrophils, conversely, showed enrichment of proteins involved in immune regulation, which is in line with their previously published capacity for suppressing T-cell–suppressing proliferation.[11] It is unknown, however, whether the capacity of CD62L^{dim} neutrophils for suppressing T-cell proliferation is in any way related to their low capacity for protein production.

In contrast to the banded neutrophils, CD62L^{dim} neutrophils had kinetics similar to those of segmented neutrophils, with respect to maturation time and disappearance rates from peripheral blood. This suggests that CD62L^{dim} neutrophils need the same time to mature as segmented neutrophils and are thus not simply aged segmented neutrophils. These results are in agreement with a previous study describing the maturation time of CD62L^{dim} neutrophils in a patient with pernicious anemia.[16] It should be noted, however, that the hypersegmentation observed in pernicious anemia is caused by defects in the DNA replication machinery,[46] which causes banded neutrophils to immediately mature into hypersegmented neutrophils.[18] Because the maturation time of CD62L^{dim} neutrophils after the last DNA synthesis was at least 5 days, it is unlikely that the DNA replication defects causing hypersegmentation in pernicious anemia caused the hypersegmentation in the cells observed 3 hours after acute inflammation. The highly similar kinetics of segmented and CD62L^{dim} neutrophils were not reflected by comparable protein expression profiles. Hierarchical clustering of the proteomes of the different subsets revealed the segmented subset to be more similar to the less mature banded neutrophils than to the CD62L^{dim} neutrophils. Thus, the difference between segmented and CD62L^{dim} neutrophils is larger than the difference caused by 2 days of maturation from banded to segmented neutrophils.

The large difference in the proteomes of CD62L^{dim} neutrophils compared with the other 2 subsets raises the issue of the putative origin

**Table 1. Top 10 most significantly enriched GO terms per cluster**

Cluster	FDR-corrected *P*	Enrichment	Type
Cluster 1: CD62L^{dim} ↑			
Extracellular space	4.98E-09	2.43	Component
Extracellular region	1.98E-08	2.69	Component
Plasma membrane	5.60E-06	1.58	Component
Response to organic substance	1.08E-05	1.86	Function
Defense response	1.40E-05	1.86	Function
Response to external stimulus	1.75E-05	2.07	Function
Response to oxygen-containing compound	2.22E-05	2.04	Function
Response to external biotic stimulus	2.41E-05	2.25	Function
Response to chemical	2.52E-05	1.69	Function
Response to biotic stimulus	3.41E-05	2.22	Function
Cluster 2: CD62L^{dim} ↓			
Ribonucleoprotein complex	3.72E-07	2.25	Component
Nucleic acid binding	1.01E-05	1.61	Function
RNA binding	2.02E-05	1.66	Function
RNA metabolic process	4.30E-05	1.82	Process
Poly(A) RNA binding	9.61E-05	1.7	Function
Nucleic acid metabolic process	3.81E-04	1.67	Process
Structural constituent of ribosome	9.23E-04	2.99	Function
Ribosomal subunit	1.55E-03	2.91	Component
mRNA metabolic process	1.82E-03	2.04	Process
Translational elongation	2.04E-03	2.89	Process
Cluster 4: band > segmented > CD62L^{dim}			
Ribonucleoprotein complex	1.07E-15	2.34	Component
Ribosomal subunit	2.57E-13	3.55	Component
RNA metabolic process	4.25E-13	1.89	Process
Cotranslational protein targeting to membrane	4.97E-13	3.32	Process
SRP-dependent cotranslational protein targeting to membrane	5.26E-13	3.36	Process
Protein targeting to ER	7.39E-13	3.28	Process
Nucleic acid metabolic process	7.50E-13	1.78	Process
Translational initiation	9.36E-13	3.03	Process
Protein localization to ER	1.36E-12	3.2	Process
Establishment of protein localization to ER	1.54E-12	3.2	Process
Cluster 6: CD62L^{dim} > segmented > band			
Extracellular vesicular exosome	2.32E-04	1.26	Component
Extracellular vesicle	2.90E-04	1.26	Component
Extracellular membrane-bounded organelle	3.86E-04	1.26	Component
Vesicle	5.18E-04	1.23	Component
Extracellular region part	5.57E-04	1.24	Component
Extracellular organelle	5.80E-04	1.26	Component
Membrane-bounded vesicle	8.88E-04	1.25	Component
Actin binding	7.31E-03	2.18	Function
Negative regulation of Wnt signaling pathway	2.00E-02	2.45	Process
Nicotinamide nucleotide metabolic process	2.02E-02	3.72	Process

ER, endoplasmic reticulum; FDR, false-discovery rate; SRP, signal recognition particle.

of these cells. It is less likely that the CD62L^{dim} neutrophil subset originates from mature neutrophils in response to LPS. Although it has been shown that neutrophils isolated from healthy individuals can produce novel proteins after incubation with high doses of LPS in vitro (100 ng/mL),[27] this did not seem to occur in our study for various reasons. In vitro experiments showing LPS-induced neutrophil activation use doses in the upper nanomolar range, whereas the dose used in our study was 2 ng/kg body weight (~50 pg/mL plasma).[47] To our knowledge, no studies have shown neutrophils to be directly responsive in the lower picomolar range. This consideration is in line with the results coming from the comparison between our data with the proteomes published by Fessler et al,[47] who studied LPS-induced changes in neutrophils activated in vitro. Only 3 of 18 differentially expressed proteins found in neutrophils activated by LPS in vitro showed behavior similar to that seen in our proteome profiling, whereas

an additional 4 proteins showed the opposite behavior (supplemental Table 1). This makes it unlikely that CD62L^{dim} neutrophils are generated in direct response to LPS stimulation. In addition, all proteins involved in transcription, translation, and mRNA/protein transport that we detected in our proteome analysis were least abundant in CD62L^{dim} neutrophils (supplemental Figure 5). This indicates that CD62L^{dim} neutrophils have an even lower capacity for protein production than segmented neutrophils, while having a higher expression of 336 proteins compared with segmented and banded cells (Figure 4, cluster 1). Therefore, we propose that the CD62L^{dim} neutrophil phenotype is not rapidly induced from normal neutrophils in response to LPS but instead is a neutrophil subset that enters the bloodstream in response to inflammation.

The existence of neutrophil subsets residing outside of the circulation is supported by the fact that under homeostasis, large

Figure 5. GO enrichment analysis for protein involvement in cellular processes. The 7 clusters from Figure 4 were subjected to GO enrichment analysis. After correction for multiple testing, 4 clusters revealed significant GO enrichments, which are plotted based on semantic similarities (ie, similar terms grouped together). Colors indicate false-discovery rate P values for each term, and the size indicates how general a term is, with a smaller size for a more specific term. Highly similar terms were removed for clarity but are provided in supplementary Table 3. ER, endoplasmic reticulum; MHC, major histocompatibility complex.

numbers of neutrophils do not reside in the peripheral blood. Neutrophils have been found in the lungs, spleen, liver, and bone marrow or can be recruited from the marginated pool.[6,48,49] In addition, reverse transmigrated neutrophils have been described that return from the tissue back into the bloodstream.[50] It is yet to be determined which tissue sites are the source of the neutrophil subsets released during acute inflammation. Reverse transmigrated neutrophils are not a likely source of CD62L^{dim} neutrophils, because CD62L^{dim} neutrophils do not exhibit the profile of reverse migrated cells: no increased expression of ICAM-1 (CD54) and no decreased CXCR1 or CXCR2 expression as determined by flow cytometric analysis[11] as well as by proteomics (supplemental Table 2). Also, the high expression of CD11c on CD62L^{dim} neutrophils is not found on reverse migrated neutrophils.[50] The marginated pool does not seem a likely source of CD62L^{dim} neutrophils either, because it consists of

neutrophils with a similar phenotype as those in the circulation.[5,49,51] In contrast, the increase in neutrophil numbers after LPS results from the entrance of cells into the bloodstream with different characteristics than those present in homeostasis.[5]

CD62L^{dim} neutrophils have been described in the bone marrow, albeit at lower numbers than banded and segmented neutrophils.[20] Therefore, the bone marrow is also a potential source of CD62L^{dim} neutrophils. Alternatively, neutrophil reserves have been described in the liver and spleen, and these are therefore also potential organs from which CD62L^{dim} neutrophils are recruited after LPS injection.[6,48,49] The kinetics of ^{2}H-glucose labeling depend on both blood and bone marrow kinetics.[52,53] The fact that mature and CD62L^{dim} neutrophils show similar label kinetics suggests a shared progenitor and similar kinetics in bone marrow and blood for the 2 cell types, but the exact developmental relation between the subsets remains to be elucidated.

Taken together, our study shows that CD62L[dim] neutrophils detected in the bloodstream after LPS challenge are of similar age as segmented neutrophils but have a proteome profile that places them apart from both segmented and the 2-day-younger banded neutrophils. Therefore, we propose CD62L[dim] is a subset of neutrophils that are only recruited to the bloodstream during acute inflammatory conditions, where they can engage in immune regulation to fine tune acute immune responses.

Acknowledgments

Authorship

Contribution: T.T. isolated cells, analyzed samples for ^{2}H enrichment, and performed all statistical analyses; P.W. performed protein identification and quantifications, supervised by A.S. and A.J.R.H. T.T. performed analysis of the proteomics data, supervised by A.S. and A.J.R.H.; M.H. was responsible for volunteer screenings and lipopolysaccharide injections and collected clinical data; M.H. and T.T. performed 6,6-^{2}H$_2$ labeling; A.J.R.H., A.S., J.A.M.B., K.T., L.P.L., P.P., N.V., and L.K. participated in the design, interpretation, and coordination of the study; T.T. wrote the first draft of the manuscript, which was revised with the help of all other authors; and all authors read and approved the final manuscript.

Conflict-of-interest disclosure: A.S. is currently employed by Janssen, Pharmaceutical Companies of Johnson & Johnson. The work described in this manuscript was entirely executed before and without affiliation with the work of A.S. at Janssen. As such there is no relationship at all between this commercial company and the currently presented study. The remaining authors declare no competing financial interests.

ORCID profiles: L.K., 0000-0002-5636-6453.

Correspondence: Leo Koenderman, HP. E 03.511, Heidelberglaan 100, 3584CX Utrecht, The Netherlands; e-mail: l.koenderman@umcutrecht.nl.

References

1. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. *Nat Med.* 2009;15(5):496-497.

2. Tecchio C, Micheletti A, Cassatella MA. Neutrophil-derived cytokines: facts beyond expression. *Front Immunol.* 2014;5:508.

3. Rørvig S, Østergaard O, Heegaard NH, Borregaard N. Proteome profiling of human neutrophil granule subsets, secretory vesicles, and cell membrane: correlation with transcriptome profiling of neutrophil precursors. *J Leukoc Biol.* 2013;94(4):711-721.

4. Pillay J, Tak T, Kamp VM, Koenderman L. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. *Cell Mol Life Sci.* 2013;70(20):3813-3827.

5. Athens JW, Haab OP, Raab SO, et al. Leukokinetic studies. IV. The total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. *J Clin Invest.* 1961;40:989-995.

6. Puga I, Cols M, Barra CM, et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. *Nat Immunol.* 2011;13(2):170-180.

7. Mandruzzato S, Solito S, Falisi E, et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. *J Immunol.* 2009;182(10):6562-6568.

8. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. *Cancer Res.* 2001;61(12):4756-4760.

9. Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. *Cancer Res.* 2009;69(4):1553-1560.

10. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol.* 2009;9(3):162-174.

11. Pillay J, Kamp VM, van Hoffen E, et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. *J Clin Invest.* 2012;122(1):327-336.

12. Hao S, Andersen M, Yu H. Detection of immune suppressive neutrophils in peripheral blood samples of cancer patients. *Am J Blood Res.* 2013;3(3):239-245.

13. Hietbrink F, Koenderman L, Althuizen M, Pillay J, Kamp V, Leenen LP. Kinetics of the innate immune response after trauma: implications for the development of late onset sepsis. *Shock.* 2013;40(1):21-27.

14. Nauseef WM, Borregaard N. Neutrophils at work. *Nat Immunol.* 2014;15(7):602-611.

15. Cronkite EP, Fliedner TM, Bond VP, Rubini JR. Dynamics of hemopoietic proliferation in man and mice studied by H3-thymidine incorporation into DNA. *Ann N Y Acad Sci.* 1959;77:803-820.

16. Fliedner TM, Cronkite EP, Killmann SA, Bond VP. Granulocytopoiesis. II. Emergence and pattern of labeling of neutrophilic granulocytes in humans. *Blood.* 1964;24:683-700.

17. Casanova-Acebes M, Pitaval C, Weiss LA, et al. Rhythmic modulation of the hematopoietic niche through neutrophil clearance. *Cell.* 2013;153(5):1025-1035.

18. Jones OP. Origin of neutrophils in pernicious anemia (Cooke's macropolycytes): biopsies of bone marrow. *Arch Intern Med.* 1937;60(6):1002-1015.

19. Donohue DM, Reiff RH, Hanson ML, Betson Y, Finch CA. Quantitative measurement of the erythrocytic and granulocytic cells of the marrow and blood. *J Clin Invest.* 1958;37(11):1571-1576.

20. Bohinjec J. Myelokathexis: chronic neutropenia with hyperplastic bone marrow and hypersegmented neutrophils in two siblings. *Blut.* 1981;42(3):191-196.

21. Lowry SF. Human endotoxemia: a model for mechanistic insight and therapeutic targeting. *Shock.* 2005;24(suppl 1):94-100.

22. Calvano SE, Xiao W, Richards DR, et al; Inflamm and Host Response to Injury Large Scale Collab. Res. Program. A network-based analysis of systemic inflammation in humans. *Nature.* 2005;437(7061):1032-1037.

23. Wong HR, Freishtat RJ, Monaco M, Odoms K, Shanley TP. Leukocyte subset-derived genomewide expression profiles in pediatric septic shock. *Pediatr Crit Care Med.* 2010;11(3):349-355.

24. Visser T, Pillay J, Pickkers P, Leenen LP, Koenderman L. Homology in systemic neutrophil response induced by human experimental endotoxemia and by trauma. *Shock.* 2012;37(2):145-151.

25. de Kleijn S, Kox M, Sama IE, et al. Transcriptome kinetics of circulating neutrophils during human experimental endotoxemia. *PLoS One.* 2012;7(6):e38255.

26. de Kleijn S, Langereis JD, Leentjens J, et al. IFN-γ-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1. *PLoS One.* 2013;8(8):e72249.

27. Zucker-Franklin D. Atlas of Blood Cells: Function and Pathology. Milan, Italy: Edi. Ermes; 1988.

28. Borregaard N, Sehested M, Nielsen BS, Sengeløv H, Kjeldsen L. Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase is a marker of terminal neutrophil differentiation. *Blood.* 1995;85(3):812-817.

29. Macallan DC, Fullerton CA, Neese RA, Haddock K, Park SS, Hellerstein MK. Measurement of cell proliferation by labeling of DNA with stable isotope-labeled glucose: studies in vitro, in animals, and in humans. *Proc Natl Acad Sci USA.* 1998;95(2):708-713.

30. Macallan DC, Asquith B, Zhang Y, et al. Measurement of proliferation and disappearance of rapid turnover cell populations in human studies

using deuterium-labeled glucose. *Nat Protoc*. 2009;4(9):1313-1327.

31. Leentjens J, Kox M, Koch RM, et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. *Am J Respir Crit Care Med*. 2012;186(9):838-845.

32. Kox M, van Eijk LT, Zwaag J, et al. Voluntary activation of the sympathetic nervous system and attenuation of the innate immune response in humans. *Proc Natl Acad Sci USA*. 2014; 111(20):7379-7384.

33. Wijten P, van Holten T, Woo LL, et al. High precision platelet releasate definition by quantitative reversed protein profiling–brief report. *Arterioscler Thromb Vasc Biol*. 2013; 33(7):1635-1638.

34. Vizcaíno JA, Reisinger F, Côté R, Martens L. PRIDE: Data submission and analysis. *Curr Protoc Protein Sci*. 2010;Chapter 25:Unit 25.4.

35. Suzuki R, Shimodaira H. Pvclust: an R package for assessing the uncertainty in hierarchical clustering. *Bioinformatics*. 2006;22(12): 1540-1542.

36. Kumar L, E Futschik M. Mfuzz: a software package for soft clustering of microarray data. *Bioinformation*. 2007;2(1):5-7.

37. Schwämmle V, Jensen ON. A simple and fast method to determine the parameters for fuzzy c-means cluster analysis. *Bioinformatics*. 2010; 26(22):2841-2848.

38. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. *BMC Bioinformatics*. 2009;10:48.

39. Gene Ontology Consortium: *Homo sapiens* gene ontology database. Available at: http:// geneontology.org/. Accessed 20 January 2015.

40. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc B*. 1995;57(1): 289-300.

41. Supek F, Bošnjak M, Škunca N, Šmuc T. REVIGO summarizes and visualizes long lists of gene ontology terms. *PLoS One*. 2011; 6(7):e21800.

42. van der Meer W, Pickkers P, Scott CS, van der Hoeven JG, Gunnewiek JK. Hematological indices, inflammatory markers and neutrophil CD64 expression: comparative trends during experimental human endotoxemia. *J Endotoxin Res*. 2007;13(2):94-100.

43. Christensen RD, Bradley PP, Rothstein G. The leukocyte left shift in clinical and experimental neonatal sepsis. *J Pediatr*. 1981;98(1):101-105.

44. Wheeler JG, Chauvenet AR, Johnson CA, Block SM, Dillard R, Abramson JS. Buffy coat transfusions in neonates with sepsis and neutrophil storage pool depletion. *Pediatrics*. 1987;79(3):422-425.

45. Glasser L, Fiederlein RL. Functional differentiation of normal human neutrophils. *Blood*. 1987;69(3):937-944.

46. Thomas ED, Lochte HL Jr. Studies on the biochemical defect of pernicious anemia. I. In vitro observations on oxygen consumption, heme synthesis and deoxyribonucleic acid synthesis by

pernicious anemia bone marrow. *J Clin Invest*. 1958;37(2):166-171.

47. Fessler MB, Malcolm KC, Duncan MW, Worthen GS. A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. *J Biol Chem*. 2002;277(35):31291-31302.

48. Saverymuttu SH, Peters AM, Keshavarzian A, Reavy HJ, Lavender JP. The kinetics of 111indium distribution following injection of 111indium labelled autologous granulocytes in man. *Br J Haematol*. 1985;61(4):675-685.

49. Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. Neutrophil kinetics in health and disease. *Trends Immunol*. 2010;31(8): 318-324.

50. Buckley CD, Ross EA, McGettrick HM, et al. Identification of a phenotypically and functionally distinct population of long-lived neutrophils in a model of reverse endothelial migration. *J Leukoc Biol*. 2006;79(2):303-311.

51. Athens JW, Raab SO, Haab OP, et al. Leukokinetic studies. III. The distribution of granulocytes in the blood of normal subjects. *J Clin Invest*. 1961;40:159-164.

52. Li KW, Turner SM, Emson CL, Hellerstein MK, Dale DC. Deuterium and neutrophil kinetics. *Blood*. 2011;117(22):6052-6053.

53. Pillay J, den Braber I, Vrisekoop N, et al. Response: The in vivo half-life of human neutrophils. *Blood*. 2011;117(22):6053-6054.